Search results
Results From The WOW.Com Content Network
Milrinone, sold under the brand name Primacor, is a pulmonary vasodilator [2] used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance.
PDE3 inhibitors are indicated as inotropics for the therapy of acute heart failure if catecholamines are ineffective. [2] Well controlled studies have shown that these drugs generally increase mortality, [3] when used for the therapy of acute heart failure, so they have to be applied under close observation. [1]
Specifically, in patients experiencing inadequate blood perfusion (with blood pressure below 80 mmHg), the American Heart Association / American College of Cardiology (ACC/AHA), recommends the use of Dobutamine and Milrinone. [75] Whereas in clinically stable patients with sufficient perfusion, cardiac inotrope use is advised against. [76]
The following are medications commonly prescribed cardiac pharmaceutical agents. The specificity of the following medications is highly variable, and often are not particularly specific to a given class. As such, they are listed as are commonly accepted.
Amrinone, milrinone and enoximone are used clinically for short-term treatment of cardiac failure. These drugs mimic sympathetic stimulation and increase cardiac output. Anagrelide [24] Cilostazol is used in the treatment of intermittent claudication. Pimobendan is FDA approved for veterinary use in the treatment of heart failure in animals.
Medications used include: diuretic agents, vasodilator agents, positive inotropes, ACE inhibitors, beta blockers, and aldosterone antagonists (e.g., spironolactone). Some medications which increase heart function, such as the positive inotrope milrinone, lead to increased death, and are contraindicated. [9] [10]
Early studies in patients with heart failure showed that amrinone produced short-term hemodynamic improvement, but had limited long-term clinical benefit. [7] Some serious side effects of long term administration included sustained ventricular tachycardia resulting in circulatory collapse, worsening myocardial ischemia, acute myocardial ...
Torrent Pharmaceuticals was established in 1959 by U. N. Mehta as Trinity Laboratories. It was renamed as Torrent Pharmaceuticals in 1971. [5]In 1997, Torrent Pharma and Sanofi established a 50:50 joint venture called Sanofi Torrent for selling Torrent Pharma's products. [6]